SEC Investigates Elan Over Disclosures of Clinical Trial Data and Side Effect Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
At issue: July 2008 reports of PML cases linked to Tysabri and key trial data for its Alzheimer's medication; Wyeth also gets a subpoena.
You may also be interested in...
Elan Says It Has Fixed The Biogen Breach, And Gives J&J a $115 Million Discount
The three-way drama heads toward a resolution -- if Biogen Idec accepts Elan's moves.
Judge Says Elan's J&J Deal Violates Tysabri Contract, Handing Biogen A Victory
Biogen Idec's lawyers took heat all day Thursday from a federal judge, but in the end she ruled in their favor. Now, Elan has 23 days to fix the breach.
Wyeth’s Pipeline Star Bapineuzumab Looks More Long Shot Than Sure Bet
Following the release of lackluster Phase II efficacy data on bapineuzumab in Alzheimer’s disease patients, talk of Wyeth as a takeover target resurfaces.